PL2117571T3 - Epitop receptora aktywatora plazminogenu typu urokinazy - Google Patents

Epitop receptora aktywatora plazminogenu typu urokinazy

Info

Publication number
PL2117571T3
PL2117571T3 PL07862653T PL07862653T PL2117571T3 PL 2117571 T3 PL2117571 T3 PL 2117571T3 PL 07862653 T PL07862653 T PL 07862653T PL 07862653 T PL07862653 T PL 07862653T PL 2117571 T3 PL2117571 T3 PL 2117571T3
Authority
PL
Poland
Prior art keywords
urokinase
plasminogen activator
type plasminogen
activator receptor
receptor epitope
Prior art date
Application number
PL07862653T
Other languages
English (en)
Inventor
Graham Parry
Andrew P. Mazar
Original Assignee
Monopar Therapeutics Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Monopar Therapeutics Inc. filed Critical Monopar Therapeutics Inc.
Publication of PL2117571T3 publication Critical patent/PL2117571T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
PL07862653T 2006-12-08 2007-12-07 Epitop receptora aktywatora plazminogenu typu urokinazy PL2117571T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US87362706P 2006-12-08 2006-12-08
US93003407P 2007-05-11 2007-05-11

Publications (1)

Publication Number Publication Date
PL2117571T3 true PL2117571T3 (pl) 2017-08-31

Family

ID=39512272

Family Applications (1)

Application Number Title Priority Date Filing Date
PL07862653T PL2117571T3 (pl) 2006-12-08 2007-12-07 Epitop receptora aktywatora plazminogenu typu urokinazy

Country Status (9)

Country Link
US (1) US8105602B2 (pl)
EP (1) EP2117571B1 (pl)
JP (2) JP2010512324A (pl)
CA (1) CA2671971C (pl)
DK (1) DK2117571T3 (pl)
ES (1) ES2636451T3 (pl)
PL (1) PL2117571T3 (pl)
PT (1) PT2117571T (pl)
WO (1) WO2008073312A2 (pl)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1765397T3 (da) * 2004-05-25 2013-02-04 Tactic Pharma Llc Inhiberende antistoffer, som binder komplekset af urokinase-type-plasminogenaktivator (uPA) og dens receptor (uPAR)
PT2117571T (pt) 2006-12-08 2017-06-14 Monopar Therapeutics Inc Resumo
US8697081B2 (en) * 2008-04-09 2014-04-15 The Regents Of The University Of Michigan Method of modulating neovascularization
CN102812047B (zh) * 2009-12-09 2015-08-26 拜耳制药股份公司 抗C4.4a抗体及其用途
CA2789436C (en) * 2010-02-12 2020-10-06 The Regents Of The University Of California Upar binding agents and methods of use thereof
BR112013016107A2 (pt) * 2010-12-22 2017-04-04 Ifom Fond Inst Firc Di Oncologia Molecolare molécula dimérica, método de tratamento de câncer, composição farmacêutica e kit para o diagnóstico de uma patologia ou tumor mediado(a) por upar
CA2842281A1 (en) 2011-08-05 2013-02-14 Ifom Fondazione Istituto Firc Di Oncologia Molecolare Constitutively active upar variants and their use for the generation and isolation of inhibitory antibodies
GB201121308D0 (en) 2011-12-12 2012-01-25 Cell Medica Ltd Process
WO2013119947A1 (en) 2012-02-09 2013-08-15 Baylor College Of Medicine Pepmixes to generate multiviral ctls with broad specificity
WO2015004148A1 (en) 2013-07-08 2015-01-15 Ifom Fondazione Istituto Firc Di Oncologia Molecolare Biomarker of plasminogen activation system and/or of upar/vn interaction and uses thereof
ES2744175T3 (es) * 2013-08-01 2020-02-24 Massachusetts Gen Hospital Biomarcadores suPAR no glucosilados y usos de los mismos
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
IL258090B2 (en) 2015-09-18 2023-04-01 Baylor College Medicine Immunogenic detection of antigen from a pathogen and adjustment of effective clinical treatment
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
JP7140362B2 (ja) * 2018-04-09 2022-09-21 国立大学法人東海国立大学機構 活性型組換えアクロシン
CN115867570A (zh) * 2020-06-15 2023-03-28 莫诺帕医疗公司 精确放射免疫治疗靶向尿激酶纤溶酶原激活剂受体（uPAR）以治疗严重COVID-19疾病
US20220378956A1 (en) * 2021-05-21 2022-12-01 Northstar Medical Technologies Llc Trivalent Radioisotope Bio-Targeted Radiopharmaceutical, Methods Of Preparation And Use
CN116410312A (zh) * 2021-12-29 2023-07-11 博生吉医药科技(苏州)有限公司 一种新型upar单域抗体的开发
WO2023172886A2 (en) * 2022-03-07 2023-09-14 Rush University Medical Center Novel treatment of diabetes and kidney disease by inhibition of d2d3 a proteolytic upar protein
CN117264061B (zh) * 2023-11-22 2024-03-01 中山大学附属第八医院（深圳福田） 一种识别uPAR的纳米抗体及其应用

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US5057313A (en) 1986-02-25 1991-10-15 The Center For Molecular Medicine And Immunology Diagnostic and therapeutic antibody conjugates
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
GB8721023D0 (en) 1987-09-07 1987-10-14 Lepetit Spa Modified plasminogen activators
IT1228881B (it) 1988-08-12 1991-07-09 Lepetit Spa Anticorpo monoclonale specifico per l'epitopo dell'urochinasi prourichinasi corrispondente alla regione denominata gfd
US5066789A (en) 1988-09-30 1991-11-19 Neorx Corporation Targeting substance-diagnostic/therapeutic agent conjugates having Schiff base linkages
EP0467932B1 (en) * 1989-04-07 2000-10-18 Cancerforskningsfonden af 1989 (fonden til fremme af eksperimentel cancerforskning) Urokinase-type plasminogen activator receptor
US5519120A (en) 1989-04-07 1996-05-21 Cancerforskningsfondet Af 1989 Urokinase-type plasminogen activator receptor antibodies
US5891664A (en) 1989-04-07 1999-04-06 Cancerforskningsfondet Af 1989 Vectors and methods for recombinant production of uPA-binding fragments of the human urokinase-type plasminogen receptor (uPAR)
US5443816A (en) 1990-08-08 1995-08-22 Rhomed Incorporated Peptide-metal ion pharmaceutical preparation and method
EP1281404A3 (en) 1990-10-18 2004-04-07 Cancerforskningsfonden af 1989 (fonden til fremme af eksperimentel cancerforskning) Use of antibodies against the urokinase receptor
US5561220A (en) 1991-02-08 1996-10-01 Diatech, Inc. Technetium-99m labeled peptides for imaging inflammation
EP0642354A4 (en) 1991-11-18 1995-07-12 Univ Michigan METHODS FOR DETECTING AND ISOLATING uPA-R AND INHIBITING THE BINDING OF uPA TO uPA-R.
US5556609A (en) 1992-02-20 1996-09-17 Rhomed Incorporated YIGSR peptide radiopharmaceutical applications
DE69328092T2 (de) 1992-05-28 2000-07-20 Univ Toledo Bereitstellung einer für krebszellen cytotoxischen verbindung unter verwendung des weges von plasminogenaktivatormaterial
US5608110A (en) 1993-06-15 1997-03-04 Bracco International B.V. Heteroatom-bearing ligands and metal complexes thereof
WO1995004281A1 (en) 1993-07-27 1995-02-09 THE UNITED STATES GOVERNMENT, represented by THE ADMINISTRATOR OF THE NATIONAL AERONAUTICS AND SPACE ADMINISTRATION Quantitative method of measuring cancer cell urokinase and metastatic potential
US5532132A (en) 1993-09-28 1996-07-02 President And Fellows Of Harvard University Method for regulating formation of a complex of plasminogen activator, its receptor and inhibitor
JP2852192B2 (ja) 1994-07-08 1999-01-27 カンセアフォースクニングスフォンデン・アフ・１９８９（フォンデン・チル・フレメ・アフ・エクスペリメンテル・カンセアフォースクニング） ｕＰＡＲのドメイン２＋３のｕＰＡ結合部位および抗体
US5618513A (en) 1995-06-07 1997-04-08 Mallinckrodt Medical, Inc. Method for preparing radiolabeled peptides
AU5711196A (en) 1996-03-14 1997-10-01 Human Genome Sciences, Inc. Apoptosis inducing molecule i
CA2248868A1 (en) 1996-03-22 1997-09-25 Human Genome Sciences, Inc. Apoptosis inducing molecule ii
CA2309541C (en) 1997-11-03 2011-01-11 Human Genome Sciences, Inc. Vegi, an inhibitor of angiogenesis and tumor growth
US6077508A (en) 1998-03-23 2000-06-20 American Diagnostica Inc. Urokinase plasminogen activator receptor as a target for diagnosis of metastases
ATE350661T1 (de) 1999-04-13 2007-01-15 Wilex Ag Diagnostischer und therapeutischer einsatz von antikörpern gegen den urokinase-rezeptor
WO2002058714A2 (en) 2001-01-25 2002-08-01 Fondazione Centro San Raffaele Del Monte Tabor Methods and agents modulating upa/upar activity
US6846484B2 (en) 2001-12-28 2005-01-25 Regents Of The University Of Minnesota DTAT fusion toxin
AU2003237779B2 (en) 2002-02-13 2008-06-26 American Diagnostica Inc. Methods for selecting treatment regimens and predicting outcomes in cancer patients
AU2003216512A1 (en) 2002-03-18 2003-10-08 Dyax Corporation Integrin ligand
KR100470535B1 (ko) 2002-06-27 2005-02-22 재단법인서울대학교산학협력재단 유피에이 항체 부착 이뮤노리포좀
WO2004099780A1 (en) 2003-05-06 2004-11-18 Rigshospitalet Immunoassays for the detection of urokinase receptor forms
AU2004290585A1 (en) 2003-11-18 2005-06-02 Attenuon Llc Antibodies and/or conjugates thereof which bind to the amino terminal fragment of urokinase, compositions and uses thereof
US7541159B2 (en) 2004-04-14 2009-06-02 The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration Molecular-specific urokinase antibodies
DK1765397T3 (da) 2004-05-25 2013-02-04 Tactic Pharma Llc Inhiberende antistoffer, som binder komplekset af urokinase-type-plasminogenaktivator (uPA) og dens receptor (uPAR)
EP1851543A2 (en) * 2005-02-24 2007-11-07 Compugen Ltd. Novel diagnostic markers, especially for in vivo imaging, and assays and methods of use thereof
PT2117571T (pt) 2006-12-08 2017-06-14 Monopar Therapeutics Inc Resumo

Also Published As

Publication number Publication date
CA2671971A1 (en) 2008-06-19
US20080199476A1 (en) 2008-08-21
WO2008073312B1 (en) 2008-12-18
JP2010512324A (ja) 2010-04-22
WO2008073312A3 (en) 2008-10-30
WO2008073312A2 (en) 2008-06-19
EP2117571A4 (en) 2010-08-04
JP2014224134A (ja) 2014-12-04
EP2117571A2 (en) 2009-11-18
PT2117571T (pt) 2017-06-14
CA2671971C (en) 2021-03-30
JP6019457B2 (ja) 2016-11-02
US8105602B2 (en) 2012-01-31
EP2117571B1 (en) 2017-03-08
DK2117571T3 (en) 2017-05-08
ES2636451T3 (es) 2017-10-05

Similar Documents

Publication Publication Date Title
PL2117571T3 (pl) Epitop receptora aktywatora plazminogenu typu urokinazy
GB2436451B (en) Dynamic vibrational control
GB2436905B (en) Vibrator
GB2438255B (en) Vibrator
GB0614947D0 (en) Epitope reduction therapy
IL192980A0 (en) Super soft foams
GB0700345D0 (en) Vibrator
HK1146089A1 (en) Recombinantly modified plasmin
GB0903663D0 (en) Thermoacoustic device
AU313434S (en) Chair
EP1960900A4 (en) COMPLEMENTARY GRAPHIC PIPELINE
IL196619A0 (en) Liner
GB0623813D0 (en) Foam reduction
GB2426308B (en) Joint for plumbing
TWM299715U (en) Cushion structure for packing
GB0604439D0 (en) Liner for furniture
GB0519824D0 (en) Absorbent liner for carry or chair
GB0500270D0 (en) Pipeline construction
ZA200701700B (en) Cushion
GB0807332D0 (en) Tracj bed structures
GB0609094D0 (en) Steel set chair
AU311790S (en) Chair
AU307798S (en) Chair
AU307797S (en) Chair
AU312462S (en) Chair